PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “MYCOPLASMA”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 505 records · Page 28Linked to original sources
PubMed1981

Mycoplasma-mediated activation of normal mouse lymphocytes: induction of cytotoxic lymphocytes and lymphocyte transformation by Mycoplasma arthritidis are under Ir gene control.

The ability of M. arthritidis, a potent arthritogenic agent, to induce normal unsensitized lymphocytes to undergo blast transformation and to become nonspecifically cytotoxic for syngeneic and allogeneic target fibroblasts was found to be dependent upon the donor strain of mouse. Lymphocytes from CBA (H2k) and BALB/c (H2d) mice were identified as high responders and lymphocytes from C56BL/10 mice (H2b) as low or nonresponders. In the cytotoxicity assay the extent of cell lysis was dependent upon the origin of both the effector cell and the target cell. By comparing the ability of M. arthritidis to activate lymphocytes from various congenic and H-2 recombinant mouse strains we demonstrated that control of the degree of responsiveness was determined by the H2 gene complex. Further studies revealed that the region controlling induction of cytotoxic lymphocytes is located to the right of the I-J subregion and to the left of the D region, most probably the I-E and/or I-C subregions of the major histocompatibility complex. These observations may be of importance in regard to the susceptibility of different mouse strains to the pathogenic effects of M. arthritidis.

Animals↗
PubMed1995

[Evaluation of conventional and new generation tests for testing the humeral response to Mycoplasma pneumoniae antigens in natural infection in humans. I. Occurrence and level of mycoplasma antibodies in clinically healthy subjects].

The aim of the first stage of investigation was to determine, using the complement fixation test (CFT), immuno-electroprecipitation test (IEPT) and ELISA, the level of mycoplasmal antibodies in serum samples obtained from 114 clinically healthy persons (49 samples from children and youth up to 20 and 65 samples from blood donors). On the basis of obtained findings, antibody titer assumed to be diagnostically significant was determined on the means + 3 SD level in each test. Thus in the CF test the assumed titer > or = 20, in the IEP test--titer > or = 2, in the ELISA-IgA--titer > or = 100, in the ELISA- IgG--titer > or = 1600, in the ELISA-IgM--titer > or = 1200, in the ELISA -IgA + G + M--titer > or = 3200. The study allowed to establish that on with age the level of mycoplasmal antibodies in immunoglobulin of classes A and G rose while the titer of these antibodies of class IgM remained on the same level in persons up to 20 and then decreased almost twice in adults. It was also found that in all age groups the mean values of titer of antibodies against M. pneumoniae calculated for each test were lower than titer assumed to be diagnostically significant.

Adolescent↗
PubMed1995

[Evaluation of conventional and new generation tests for testing the humeral response to Mycoplasma pneumoniae antigens in natural infections in humans. II. Occurrence and level of mycoplasma antibodies in patients with respiratory tract infections].

The aim of the study was to observe the frequency of occurrence of mycoplasmal antibodies detected by the complement fixation test (CFT), immunoelectroprecipitation test (IEPT) and ELISA in selected groups of patients with respiratory tract infections and to determine the dependence of these antibodies on the age of patients and length of illness. 521 serum samples collected from 404 persons were examined; 378 samples were obtained from 276 patients with pneumonia and 143 from 128 patients with upper respiratory tract infections. Additionally, serum samples from 50 patients with B. pertussis were investigated in this section of the study as a control test to demonstrate the specificity of the tests. It was established that in patients with pneumonia mycoplasmal antibodies are, as a rule, detected in much higher titers than in patients with upper respiratory tract infections. On with age, the level of mycoplasmal antibodies detected in all the three tests rose in the examined patients. In the highest titers antibodies against M. pneumoniae were detected in adults within the age 21-50. As a rule mycoplasmal IgM antibodies reached a level 2-3 times higher than IgG antibodies. It was also shown that already during the first week of illness antibodies against M. pneumoniae determined by the CFT, IEPT and ELISA in the sera of the examined persons are higher than the level known to be diagnostically significant. During the second week of illness IgA and IgM antibodies have a particularly high titer while the growth of titer of IgG antibodies is relatively small. A very high level of IgM, along with progressive growth of IgG antibodies and the related gradual decrease of the index value IgM/IgG, was observed in the serum of patients up to the 4th week of illness. In some cases, in titer known to be diagnostically significant, this high level was present even many months after the appearance of disease symptoms. Antibodies against M. pneumoniae in class of immunoglobulin A disappeared the fastest. Thus it is believed that demonstrating their characteristics dynamics or detecting these antibodies in the patient's serum in the titer assumed to be diagnostically significant can indicate an acute stage of illness.

Adolescent↗